

Global HIV Clinical Trials Market Size Study, By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional Studies, Observational Studies, Expanded Access Studies), By Sponsor, By Region, and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/GE7DE2A45436EN.html>

Date: January 2025

Pages: 285

Price: US\$ 3,218.00 (Single User License)

ID: GE7DE2A45436EN

Abstracts

The global HIV clinical trials market is valued at approximately USD 1.47 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.8% over the forecast period 2024-2032. The HIV clinical trials market represents a dynamic and evolving landscape, driven by increasing innovation in drug development, heightened research and development (R&D) investments, and the global push toward achieving sustainable HIV prevention and treatment solutions. These clinical trials form the backbone of exploring advanced therapies, long-acting drugs, and gene-based treatments while ensuring safety and efficacy for the patient population. Additionally, the market benefits from the growing prevalence of HIV and the concerted efforts of public and private entities to discover more efficient cures and preventive therapies.

The rising incidence of HIV infections and increasing government initiatives to support clinical trials bolster market expansion. For example, in September 2023, the National Institutes of Health (NIH) initiated a Phase 1 clinical trial for VIR-1388, an HIV vaccine candidate, in the U.S. and South Africa. Such robust research efforts highlight the sector's commitment to transforming HIV treatment paradigms. Furthermore, the integration of advanced technologies, such as digital health platforms and data-driven analytics, has enhanced the efficiency and accessibility of clinical trials, propelling industry growth.

Global HIV Clinical Trials Market is further catalyzed by the increasing focus on reducing disparities in treatment access and the implementation of precision medicine.

Pharmaceutical and biopharmaceutical companies are the primary sponsors, accounting for significant market revenue due to their sustained investments in novel therapies, including gene therapy and vaccine development. For instance, Addimmune, a biotech company, launched its operations in June 2023 to focus on HIV cure technologies, leveraging successful Phase I trials to establish new benchmarks in gene and cell therapy.

The market is not without its challenges, including the high costs of conducting clinical trials and regulatory hurdles. However, the increasing number of collaborative efforts between academic institutions, non-profits, and the private sector to fund and conduct these trials provides a conducive growth environment. North America dominated the global HIV clinical trials market in 2023, driven by its advanced healthcare infrastructure, high R&D expenditure, and the presence of leading clinical research organizations. The Asia-Pacific region is anticipated to witness the fastest growth, owing to its cost-efficient trial setups, skilled labor, and diverse patient pools.

The following companies play a significant role in the global HIV clinical trials market:

Major market players included in this report are:

PPD Inc.

IQVIA Inc.

Parexel International Corporation

ICON plc

Syneos Health

WuXi AppTec

Janssen Global Services, LLC

Gilead Sciences, Inc.

Bionor Holding AS

Charles River Laboratories

GSK plc.

SGS SA

ViiV Healthcare

Medpace

Covance Inc.

The detailed segments and sub-segment of the market are explained below:

By Phase:

Phase I

Phase II

Phase III

Phase IV

By Study Design:

Interventional Studies

Observational Studies

Expanded Access Studies

By Sponsor:

Pharmaceutical & Biopharmaceutical Companies

Non-Profit Organizations

Others

By Region:

North America

U.S.

Canada

Mexico

Europe

UK

Germany

France

Italy

Spain

Sweden

Denmark

Norway

Asia-Pacific

Japan

China

India

Thailand

South Korea

Australia

Latin America

Brazil

Argentina

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Years Considered for the Study:

Historical Year: 2022

Base Year: 2023

Forecast Period: 2024-2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional-level analysis for each market segment.

Detailed analysis of the geographical landscape with country-level insights into key regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations for future market approaches.

Demand-side and supply-side analysis of the market.

Contents

CHAPTER 1. GLOBAL HIV CLINICAL TRIALS MARKET EXECUTIVE SUMMARY

- 1.1. Global HIV Clinical Trials Market Size & Forecast (2022-2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Phase
 - 1.3.2. By Study Design
 - 1.3.3. By Sponsor
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL HIV CLINICAL TRIALS MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.4. Demand Side Analysis
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL HIV CLINICAL TRIALS MARKET DYNAMICS

- 3.1. Market Drivers
 - 3.1.1. Rising Incidence of HIV Cases
 - 3.1.2. Advancements in Drug Development
 - 3.1.3. Increasing Investments in Clinical Trials
- 3.2. Market Challenges
 - 3.2.1. High Cost of Clinical Trials
 - 3.2.2. Stringent Regulatory Environment
- 3.3. Market Opportunities
 - 3.3.1. Emerging Markets for Decentralized Trials

3.3.2. Integration of Digital Technologies in Trials

CHAPTER 4. GLOBAL HIV CLINICAL TRIALS MARKET INDUSTRY ANALYSIS

- 4.1. Porter's 5 Force Model
 - 4.1.1. Bargaining Power of Suppliers
 - 4.1.2. Bargaining Power of Buyers
 - 4.1.3. Threat of New Entrants
 - 4.1.4. Threat of Substitutes
 - 4.1.5. Competitive Rivalry
- 4.2. PESTEL Analysis
- 4.3. Top Investment Opportunity
- 4.4. Top Winning Strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL HIV CLINICAL TRIALS MARKET SIZE & FORECASTS BY PHASE 2022-2032

- 5.1. Segment Dashboard
- 5.2. Global HIV Clinical Trials Market by Phase, Revenue Trend Analysis, 2022-2032 (USD Million)
 - 5.2.1. Phase I
 - 5.2.2. Phase II
 - 5.2.3. Phase III
 - 5.2.4. Phase IV

CHAPTER 6. GLOBAL HIV CLINICAL TRIALS MARKET SIZE & FORECASTS BY STUDY DESIGN 2022-2032

- 6.1. Segment Dashboard
- 6.2. Global HIV Clinical Trials Market by Study Design, Revenue Trend Analysis, 2022-2032 (USD Million)
 - 6.2.1. Interventional Studies
 - 6.2.2. Observational Studies
 - 6.2.3. Expanded Access Studies

CHAPTER 7. GLOBAL HIV CLINICAL TRIALS MARKET SIZE & FORECASTS BY

Global HIV Clinical Trials Market Size Study, By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Desi...

SPONSOR 2022-2032

7.1. Segment Dashboard

7.2. Global HIV Clinical Trials Market by Sponsor, Revenue Trend Analysis, 2022-2032 (USD Million)

7.2.1. Pharmaceutical & Biopharmaceutical Companies

7.2.2. Non-Profit Organizations

7.2.3. Others

CHAPTER 8. GLOBAL HIV CLINICAL TRIALS MARKET SIZE & FORECASTS BY REGION 2022-2032

8.1. North America HIV Clinical Trials Market

8.1.1. U.S. HIV Clinical Trials Market

8.1.2. Canada HIV Clinical Trials Market

8.1.3. Mexico HIV Clinical Trials Market

8.2. Europe HIV Clinical Trials Market

8.2.1. UK HIV Clinical Trials Market

8.2.2. Germany HIV Clinical Trials Market

8.2.3. France HIV Clinical Trials Market

8.2.4. Italy HIV Clinical Trials Market

8.2.5. Spain HIV Clinical Trials Market

8.3. Asia Pacific HIV Clinical Trials Market

8.3.1. Japan HIV Clinical Trials Market

8.3.2. China HIV Clinical Trials Market

8.3.3. India HIV Clinical Trials Market

8.3.4. Thailand HIV Clinical Trials Market

8.3.5. South Korea HIV Clinical Trials Market

8.3.6. Australia HIV Clinical Trials Market

8.4. Latin America HIV Clinical Trials Market

8.4.1. Brazil HIV Clinical Trials Market

8.4.2. Argentina HIV Clinical Trials Market

8.5. Middle East & Africa HIV Clinical Trials Market

8.5.1. South Africa HIV Clinical Trials Market

8.5.2. Saudi Arabia HIV Clinical Trials Market

8.5.3. UAE HIV Clinical Trials Market

8.5.4. Kuwait HIV Clinical Trials Market

CHAPTER 9. COMPETITIVE INTELLIGENCE

9.1. Key Company SWOT Analysis

9.1.1. ICON plc

9.1.2. Gilead Sciences, Inc.

9.1.3. IQVIA Inc.

9.2. Top Market Strategies

9.3. Company Profiles

CHAPTER 10. RESEARCH PROCESS

10.1. Research Process

10.1.1. Data Mining

10.1.2. Analysis

10.1.3. Market Estimation

10.1.4. Validation

10.1.5. Final Publishing

10.2. Research Attributes

10.2.1. Qualitative Analysis

10.2.2. Quantitative Analysis

10.2.3. Secondary Research

10.2.4. Primary Research

10.3. Research Methodology

10.4. Data Sources

10.5. Research Outcome and Validation

12. LIST OF TABLES

1. TABLE 1. GLOBAL HIV CLINICAL TRIALS MARKET, REPORT SCOPE

2. TABLE 2. GLOBAL HIV CLINICAL TRIALS MARKET ESTIMATES & FORECASTS BY REGION 2022-2032 (USD MILLION)

3. TABLE 3. GLOBAL HIV CLINICAL TRIALS MARKET ESTIMATES & FORECASTS BY PHASE 2022-2032 (USD MILLION)

4. TABLE 4. GLOBAL HIV CLINICAL TRIALS MARKET ESTIMATES & FORECASTS BY STUDY DESIGN 2022-2032 (USD MILLION)

5. TABLE 5. GLOBAL HIV CLINICAL TRIALS MARKET ESTIMATES & FORECASTS

Global HIV Clinical Trials Market Size Study, By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Desi...

BY SPONSOR 2022-2032 (USD MILLION)

6. TABLE 6. U.S. HIV CLINICAL TRIALS MARKET ESTIMATES & FORECASTS BY SPONSOR 2022-2032 (USD MILLION)

7. TABLE 7. EUROPE HIV CLINICAL TRIALS MARKET ESTIMATES & FORECASTS BY SPONSOR 2022-2032 (USD MILLION)

8. TABLE 8. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET ESTIMATES & FORECASTS BY PHASE 2022-2032 (USD MILLION)

9. TABLE 9. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE BREAKDOWN BY COUNTRY, 2022-2032

10. TABLE 10. CANADA HIV CLINICAL TRIALS MARKET BREAKDOWN BY STUDY DESIGN, 2022-2032

11. TABLE 11. BRAZIL HIV CLINICAL TRIALS MARKET TRENDS AND FORECASTS BY PHASE, 2022-2032

12. TABLE 12. COMPETITIVE LANDSCAPE ANALYSIS BY KEY PLAYERS (2022-2032)

13. TABLE 13. SWOT ANALYSIS OF ICON PLC (2023)

14. TABLE 14. SWOT ANALYSIS OF GILEAD SCIENCES, INC. (2023)

15. TABLE 15. SWOT ANALYSIS OF IQVIA INC. (2023)

16. TABLE 16. GLOBAL PIPELINE OVERVIEW OF HIV CLINICAL TRIAL STAGES

17. TABLE 17. CLINICAL TRIAL COST BREAKDOWN BY REGION (2022-2032)

18. TABLE 18. TOP CLINICAL SITES AND INFRASTRUCTURE DETAILS BY REGION (2023)

19. TABLE 19. FDA AND EMA APPROVALS FOR HIV DRUGS (2022-2032)

20. TABLE 20. EMERGING HIV CLINICAL TRIALS BY TECHNOLOGY ADOPTION

(2022-2032)

This list is not complete. The final report contains more than 100 tables and will be updated in the final deliverable.

12. LIST OF FIGURES

1. FIG 1. GLOBAL HIV CLINICAL TRIALS MARKET, RESEARCH METHODOLOGY

2. FIG 2. GLOBAL HIV CLINICAL TRIALS MARKET, MARKET ESTIMATION TECHNIQUES

3. FIG 3. GLOBAL HIV CLINICAL TRIALS MARKET TRENDS 2022-2032

4. FIG 4. NORTH AMERICA HIV CLINICAL TRIALS MARKET SHARE BY COUNTRY (2023)

5. FIG 5. EUROPE HIV CLINICAL TRIALS MARKET SIZE AND GROWTH RATES (2022-2032)

6. FIG 6. GLOBAL HIV CLINICAL TRIALS MARKET GROWTH, PORTER'S FIVE FORCES ANALYSIS

7. FIG 7. GLOBAL HIV CLINICAL TRIALS MARKET, PESTEL ANALYSIS

8. FIG 8. HIV CLINICAL TRIALS REVENUE SHARE BY PHASE (2022 & 2032)

9. FIG 9. REVENUE CONTRIBUTION BY STUDY DESIGN (2022 VS 2032)

10. FIG 10. GLOBAL HIV CLINICAL TRIALS MARKET, BY SPONSOR 2022-2032

11. FIG 11. PIPELINE OVERVIEW: PHASE I-PHASE IV CLINICAL TRIALS

12. FIG 12. COST-EFFICIENCY OF CLINICAL TRIALS IN ASIA PACIFIC (2022 VS 2032)

13. FIG 13. TECHNOLOGICAL ADVANCEMENTS IN DIGITAL HEALTH FOR HIV TRIALS (2022-2032)

14. FIG 14. INTERVENTIONAL STUDIES' IMPACT ON PATIENT OUTCOMES (2022-2032)

15. FIG 15. EXPANDED ACCESS STUDIES MARKET SHARE BY REGION (2022 & 2032)

16. FIG 16. TOP SPONSORS' MARKET SHARE (2023)

17. FIG 17. HIV CLINICAL TRIALS FUNDING TRENDS ACROSS REGIONS (2022-2032)

18. FIG 18. DRUG APPROVAL TIMELINES FOR HIV VACCINES (2022-2032)

19. FIG 19. FDA-APPROVED HIV CLINICAL TRIALS, 2022-2032 (KEY MILESTONES)

20. FIG 20. SWOT ANALYSIS SUMMARY: KEY COMPETITORS (2023)

This list is not complete. The final report contains more than 50 figures and will be updated in the final deliverable.

I would like to order

Product name: Global HIV Clinical Trials Market Size Study, By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional Studies, Observational Studies, Expanded Access Studies), By Sponsor, By Region, and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/GE7DE2A45436EN.html>

Price: US\$ 3,218.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE7DE2A45436EN.html>